



## 2017 ASSEMBLY JOINT RESOLUTION 19

March 16, 2017 - Introduced by Representatives SINICKI, BOWEN, E. BROOKS, FIELDS, HORLACHER, KOLSTE, MILROY, MURPHY, OHNSTAD, C. TAYLOR, THIESFELDT and WACHS, cosponsored by Senators DARLING, COWLES, JOHNSON, C. LARSON, VINEHOUT and WIRCH. Referred to Committee on Rules.

\*\*\*AUTHORS SUBJECT TO CHANGE\*\*\*

1     **Relating to:** designating June 2017 as Myasthenia Gravis Awareness Month.

2             Whereas, myasthenia gravis (MG) is an autoimmune neuromuscular disease  
3     that causes chronic weakness, in which antibodies attack receptors in the body and  
4     prevent muscle contraction; and

5             Whereas, MG frequently weakens muscles that control eye movement, facial  
6     expressions, and swallowing, and its symptoms may include blurred vision, speech  
7     impairment, difficulty chewing, shortness of breath, an unstable gait, and a  
8     weakened grip; and

9             Whereas, a diagnosis of MG may be missed or delayed because its symptoms  
10    are in common with many other disorders; and

11            Whereas, in some cases MG symptoms can worsen to the point of disability,  
12    grave illness, or death, if there are gaps in or an absence of the several crucial health  
13    care treatments that can enable those who endure MG to lead productive, active lives  
14    of normal longevity; and

